A clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe. The report, which is published in the January issue of Future Cardiology, provides a comprehensive overview of the ODYSSEY MONO trial, including detail on the study design, data analysis, results and discussion on the implications ...
You have just read an article categorized health
titled Alirocumab Shows Promise as Treatment to Lower LDL-Cholesterol.
Written by:
editor - Tuesday, February 17, 2015
There are currently no comments for "Alirocumab Shows Promise as Treatment to Lower LDL-Cholesterol"
Post a Comment